Sunday 15 February 2026

One To Watch

Esperion Therapeutics

A US pharma company developing medicines to improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Company Overview

Want to Update your Company's Profile?


Latest Esperion Therapeutics News

Otsuka submits NDA in Japan for bempedoic acid
27 November 2024
Esperion monetizes bempedoic royalties
6 July 2024
New approval in Europe for Nilemdo and Nustendi
24 May 2024
Bempedoic acid meets goal in Phase III hypercholesterolemia trial
20 May 2024
More Esperion Therapeutics news >


Today's issue

FDA slaps CRL on Disc Medicine’s bitopertin NDA
Pharmaceutical
FDA slaps CRL on Disc Medicine’s bitopertin NDA
14 February 2026
Pharmaceutical
Withdrawal of EU approvals for levamisole medicines recommended
13 February 2026
Pharmaceutical
Vertex veers upwards on impressive results
13 February 2026
Pharmaceutical
Serum Institute of India inks deal with Oxford University
13 February 2026
Biotechnology
Moderna tops Q4 2025 EPS by 51c, beats on revenue
13 February 2026
Pharmaceutical
Breztri asthma results published with filings under review
13 February 2026
Biotechnology
Immunic prices private placement of up to $400 million
13 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze